Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -$737.1K | -$101.2K | -$595.3K | -$44.9K | -$41K | |
| EBITDA | -$737.1K | -$101.2K | -$595.4K | -$44.9K | -$41K | |
| Diluted EPS | -$0.01 | -$0.00 | -$0.00 | -$0.00 | -$0.00 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $13.4K | $10.7K | $8.4K | $6.6K | $28.9K | |
| Total Assets | $18.8K | $16.1K | $13.8K | $12K | $34.3K | |
| Current Liabilities | $10.3M | $9.9M | $10.2M | $11.2M | $10.8M | |
| Total Liabilities | $10.3M | $9.9M | $10.2M | $11.2M | $10.8M | |
| Total Equity | -$10.3M | -$9.9M | -$10.2M | -$11.2M | -$10.7M | |
| Total Debt | -- | -- | $274.2K | $285K | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$42.4K | -$2.7K | $44.9K | -$26.8K | -$42.1K | |
| Cash From Investing | $300 | -- | -- | -- | -- | |
| Cash From Financing | $63.6K | $106K | -$28.5K | $36.4K | $43.2K | |
| Free Cash Flow | -$42.4K | -$2.7K | $45K | -$26.8K | -$42.1K | |
Zhen Ding Resources, Inc. is engaged in seeking business partnership opportunities with companies that are in the field of exploration and extraction of precious and/or base metals, primarily in China, which are in need of funding and improved management. The company was founded on September 16, 1996 and is headquartered in Brossard, Canada.
In the current month, RBTK has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The RBTK average analyst price target in the past 3 months is --.
According to analysts, the consensus estimate is that Zhen Ding Resources, Inc. share price will drop to -- per share over the next 12 months.
Analysts are divided on their view about Zhen Ding Resources, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Zhen Ding Resources, Inc. is a Sell and believe this share price will rise from its current level to --.
The price target for Zhen Ding Resources, Inc. over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
According to Wall Street analysts, the consensus rating for Zhen Ding Resources, Inc. is a --. 0 of 0 analysts rate the stock a -- at this time.
You can purchase shares of Zhen Ding Resources, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Zhen Ding Resources, Inc. shares.
Zhen Ding Resources, Inc. was last trading at $12.22 per share. This represents the most recent stock quote for Zhen Ding Resources, Inc.. Yesterday, Zhen Ding Resources, Inc. closed at $12.22 per share.
In order to purchase Zhen Ding Resources, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Signup to receive the latest stock alerts
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Market Cap: $4.6T
P/E Ratio: 64x
Market Cap: $4T
P/E Ratio: 37x
Market Cap: $3.8T
P/E Ratio: 39x
Hut 8 Corp. [HUT] is up 0.65% over the past day.
Travere Therapeutics, Inc. [TVTX] is up 14.03% over the past day.
Structure Therapeutics, Inc. [GPCR] is down 2.36% over the past day.